Primary CNS lymphoma treatment: Current status and future directions

Tomotsugu Ichikawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare variant of non-Hodgkin’s lymphoma that is confined to the central nervous system. It comprises approximately 2 to 7% of primary central nervous system tumors and its incidence has been increasing in the immunocompetent, elderly patient population in Japan. Although high-dose methotrexate-based chemotherapy and whole-brain radiation therapy (WBRT) has improved disease control and survival in patients with PCNSL, most patients eventually experience a relapse, and uncontrolled PCNSL remains the primary cause of death. The aims of this review are to understand current treatment modalities and their problems, and novel trials that aim to improve survival and functional outcome. Currently, multiple treatment regimens using high-dose MTX-based multiagent chemotherapy have been reported, but overall survival has plateaued around 3 to 4 years. Also, WBRT produces considerable neurotoxicity, especially in elderly patients. To improve functional outcome, it has been reported that deferring WBRT was associated with reduced neurotoxicity without worsening the prognosis. To reduce recurrence after MTX-based chemotherapy, encouraging results have been published recently of trials using high-dose myeloablative chemotherapy with autologous hematopoietic stem cell transplantation (HDCT/ASCT). This strategy could replace consolidation radiotherapy. Clarification of pathogenesis and pathophysiology, including molecular analysis, is indispensable in developing new treatment modalities. Additionally, it is imperative that novel treatment modalities should be developed to improve survival and functional outcome. Deferral of radiation therapy by introducing HDCT/ASCT is one such candidate.

Original languageEnglish
Pages (from-to)99-110
Number of pages12
JournalJapanese Journal of Neurosurgery
Volume27
Issue number2
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Lymphoma
Radiotherapy
Drug Therapy
Central Nervous System
Survival
Hematopoietic Stem Cell Transplantation
Brain
Therapeutics
Recurrence
Central Nervous System Neoplasms
Methotrexate
Non-Hodgkin's Lymphoma
Cause of Death
Japan
Direction compound
Incidence
Population

Keywords

  • Chemotherapy
  • Primary central nervous system lymphoma
  • Radiotherapy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Primary CNS lymphoma treatment : Current status and future directions. / Ichikawa, Tomotsugu.

In: Japanese Journal of Neurosurgery, Vol. 27, No. 2, 01.01.2018, p. 99-110.

Research output: Contribution to journalArticle

@article{f5e72f21b6a24e9babae23838bdde8bc,
title = "Primary CNS lymphoma treatment: Current status and future directions",
abstract = "Primary central nervous system lymphoma (PCNSL) is a rare variant of non-Hodgkin’s lymphoma that is confined to the central nervous system. It comprises approximately 2 to 7{\%} of primary central nervous system tumors and its incidence has been increasing in the immunocompetent, elderly patient population in Japan. Although high-dose methotrexate-based chemotherapy and whole-brain radiation therapy (WBRT) has improved disease control and survival in patients with PCNSL, most patients eventually experience a relapse, and uncontrolled PCNSL remains the primary cause of death. The aims of this review are to understand current treatment modalities and their problems, and novel trials that aim to improve survival and functional outcome. Currently, multiple treatment regimens using high-dose MTX-based multiagent chemotherapy have been reported, but overall survival has plateaued around 3 to 4 years. Also, WBRT produces considerable neurotoxicity, especially in elderly patients. To improve functional outcome, it has been reported that deferring WBRT was associated with reduced neurotoxicity without worsening the prognosis. To reduce recurrence after MTX-based chemotherapy, encouraging results have been published recently of trials using high-dose myeloablative chemotherapy with autologous hematopoietic stem cell transplantation (HDCT/ASCT). This strategy could replace consolidation radiotherapy. Clarification of pathogenesis and pathophysiology, including molecular analysis, is indispensable in developing new treatment modalities. Additionally, it is imperative that novel treatment modalities should be developed to improve survival and functional outcome. Deferral of radiation therapy by introducing HDCT/ASCT is one such candidate.",
keywords = "Chemotherapy, Primary central nervous system lymphoma, Radiotherapy",
author = "Tomotsugu Ichikawa",
year = "2018",
month = "1",
day = "1",
doi = "10.7887/jcns.27.99",
language = "English",
volume = "27",
pages = "99--110",
journal = "Japanese Journal of Neurosurgery",
issn = "0917-950X",
publisher = "日本脳神経外科コングレス",
number = "2",

}

TY - JOUR

T1 - Primary CNS lymphoma treatment

T2 - Current status and future directions

AU - Ichikawa, Tomotsugu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Primary central nervous system lymphoma (PCNSL) is a rare variant of non-Hodgkin’s lymphoma that is confined to the central nervous system. It comprises approximately 2 to 7% of primary central nervous system tumors and its incidence has been increasing in the immunocompetent, elderly patient population in Japan. Although high-dose methotrexate-based chemotherapy and whole-brain radiation therapy (WBRT) has improved disease control and survival in patients with PCNSL, most patients eventually experience a relapse, and uncontrolled PCNSL remains the primary cause of death. The aims of this review are to understand current treatment modalities and their problems, and novel trials that aim to improve survival and functional outcome. Currently, multiple treatment regimens using high-dose MTX-based multiagent chemotherapy have been reported, but overall survival has plateaued around 3 to 4 years. Also, WBRT produces considerable neurotoxicity, especially in elderly patients. To improve functional outcome, it has been reported that deferring WBRT was associated with reduced neurotoxicity without worsening the prognosis. To reduce recurrence after MTX-based chemotherapy, encouraging results have been published recently of trials using high-dose myeloablative chemotherapy with autologous hematopoietic stem cell transplantation (HDCT/ASCT). This strategy could replace consolidation radiotherapy. Clarification of pathogenesis and pathophysiology, including molecular analysis, is indispensable in developing new treatment modalities. Additionally, it is imperative that novel treatment modalities should be developed to improve survival and functional outcome. Deferral of radiation therapy by introducing HDCT/ASCT is one such candidate.

AB - Primary central nervous system lymphoma (PCNSL) is a rare variant of non-Hodgkin’s lymphoma that is confined to the central nervous system. It comprises approximately 2 to 7% of primary central nervous system tumors and its incidence has been increasing in the immunocompetent, elderly patient population in Japan. Although high-dose methotrexate-based chemotherapy and whole-brain radiation therapy (WBRT) has improved disease control and survival in patients with PCNSL, most patients eventually experience a relapse, and uncontrolled PCNSL remains the primary cause of death. The aims of this review are to understand current treatment modalities and their problems, and novel trials that aim to improve survival and functional outcome. Currently, multiple treatment regimens using high-dose MTX-based multiagent chemotherapy have been reported, but overall survival has plateaued around 3 to 4 years. Also, WBRT produces considerable neurotoxicity, especially in elderly patients. To improve functional outcome, it has been reported that deferring WBRT was associated with reduced neurotoxicity without worsening the prognosis. To reduce recurrence after MTX-based chemotherapy, encouraging results have been published recently of trials using high-dose myeloablative chemotherapy with autologous hematopoietic stem cell transplantation (HDCT/ASCT). This strategy could replace consolidation radiotherapy. Clarification of pathogenesis and pathophysiology, including molecular analysis, is indispensable in developing new treatment modalities. Additionally, it is imperative that novel treatment modalities should be developed to improve survival and functional outcome. Deferral of radiation therapy by introducing HDCT/ASCT is one such candidate.

KW - Chemotherapy

KW - Primary central nervous system lymphoma

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85042552639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042552639&partnerID=8YFLogxK

U2 - 10.7887/jcns.27.99

DO - 10.7887/jcns.27.99

M3 - Article

AN - SCOPUS:85042552639

VL - 27

SP - 99

EP - 110

JO - Japanese Journal of Neurosurgery

JF - Japanese Journal of Neurosurgery

SN - 0917-950X

IS - 2

ER -